Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1626 1639 1675 1692
This examiner grants 52% of resolved cases
Robert H. Havlin has a large volume of 1046 resolved cases in Art Unit 1622 and Tech Center 1600. His allowance rate of 51.5% indicates an almost even split between grants and abandonments. This figure provides a moderate baseline for applicant success. The 51.5% allowance rate is a reliable metric given the 1046 resolved cases relative to the total resolutions.
The interview lift of 28.1% suggests that direct communication is a productive strategy. This lift can significantly improve the 51.5% base allowance rate, indicating the examiner is open to verbal negotiation. Practitioners should consider this tactic to move cases toward a grant in the 1046 resolved cases. The 28.1% lift is a valuable tool for overcoming rejections through active engagement.
The median days to allowance is 1030, which is the typical timeline for successful prosecution. This duration, combined with the 51.5% allowance rate, defines the standard experience in this docket. The large sample size makes the 1030 median days a stable benchmark for planning. These metrics allow for more accurate budgeting and timeline management during the patent acquisition process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18435115 | METHOD OF MAINTAINING REMISSION OF DEPRESSIVE SYMPTOMS | Final Rejection | ANTECIP BIOVENTURES II LLC |
| 18173386 | NUCLEIC ACID EXTRACTION AND AMPLIFICATION CONTROLS AND METHODS OF USE THEREOF | Final Rejection | LIFE TECHNOLOGIES CORPORATION |
| 18258711 | CRYSTALLINE FORM I OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME | Final Rejection | LG CHEM, LTD. |
| 18258717 | CRYSTALLINE FORM II OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR | Final Rejection | LG CHEM, LTD. |
| 18580674 | BAK ACTIVATORS, PHARMACEUTICAL COMPOSITIONS, AND USES IN TREATING CANCER | Non-Final OA | Emory University |
| 17653897 | FEATURIZATION OF CARBON DIOXIDE CAPTURE CHARACTERISTICS IN MOLECULES | Non-Final OA | INTERNATIONAL BUSINESS MACHINES CORPORATION |
| 18279348 | PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18058216 | METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING | Final Rejection | Becton, Dickinson and Company |
| 18872978 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES CONTAINING DEMETHYLZEYLASTERAL | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 19216139 | METHODS AND KITS FOR LABELING CELLULAR MOLECULES | Non-Final OA | University of Washington |
| 18455152 | METHODS AND KITS FOR LABELING CELLULAR MOLECULES | Final Rejection | University of Washington |
| 18188504 | METHODS AND KITS FOR LABELING CELLULAR MOLECULES | Final Rejection | University of Washington |
| 18556969 | METHODS FOR TREATING SYMPTOMS OF KABUKI SYNDROME | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 18147251 | REFINING METHOD | Final Rejection | NGK Insulators, Ltd. |
| 18589552 | New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18585280 | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18224632 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HPV-ASSOCIATED DISEASE STATES | Non-Final OA | Children's Hospital Medical Center |
| 17916843 | Synthesis of vinylic alcohol intermediates | Final Rejection | AMGEN INC. |
| 18560636 | SELF-PRESERVING COMPOSITIONS AND MULTI-USE DISPENSERS FOR ADMINISTERING ALPHA-1062 | Final Rejection | ALPHA COGNITION INC. |
| 18869103 | GCN2 MODULATOR FOR TREATING CANCER | Non-Final OA | HIBERCELL, INC. |
| 18458387 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Final Rejection | Universal Display Corporation |
| 18006681 | PROCESS FOR PRODUCING A GAS STREAM COMPRISING CARBON MONOXIDE | Final Rejection | JOHNSON MATTHEY DAVY TECHNOLOGIES LIMITED |
| 18549406 | METHOD FOR PREPARATION OF AMIDINES | Non-Final OA | VERSALIS S.P.A. |
| 18546525 | ESTROGEN RECEPTOR ALPHA ANTAGONISTS AND USES THEREOF | Final Rejection | Loyola University of Chicago |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy